CLINICAL DATA TRANSPARENCY - BENEFITS FOR PUBLIC HEALTH

The European Medicines Agency provides open access to clinical data for medicines authorised in the European Union

Academics & researchers

Enhanced scientific knowledge

Open access to data facilitates independent re-analysis and increases knowledge about medicines.

Pharmaceutical industry

Quality R&D and innovation

Shared knowledge helps developers learn from the experience of others and can lead to more efficient medicine development programmes.

Doctors

Better practice of medicine

Doctors have more information about the data underpinning the authorisation of the medicines they prescribe. This enables them to take better treatment decisions.

Patients

Better medicines

Patients, especially those who have participated in clinical trials, have information on the results of these trials. Transparency will also help to channel research efforts into areas where patients' needs for new medicines are greatest.

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH